Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study.

Humans Male Aged Female Carcinoma, Hepatocellular / pathology Liver Neoplasms / pathology Yttrium Radioisotopes Cohort Studies Retrospective Studies Ascites / drug therapy End Stage Liver Disease Australia / epidemiology Severity of Illness Index Sirtuins / therapeutic use Treatment Outcome

Barcelona Clinic Liver Cancer Staging System hepatocellular carcinoma radiation-induced liver injury selective internal radiation therapy transarterial radioembolization

Journal

Journal of gastroenterology and hepatology

ISSN: 1440-1746

Titre abrégé: J Gastroenterol Hepatol

Pays: Australia

ID NLM: 8607909

Informations de publication

Date de publication:
Nov 2022

Historique:

revised: 27 07 2022

received: 17 05 2022

accepted: 17 08 2022

pubmed: 29 8 2022

medline: 22 11 2022

entrez: 28 8 2022

Statut: ppublish

Résumé

The exact place for selective internal radiation therapy (SIRT) in the therapeutic algorithm for hepatocellular carcinoma (HCC) is debated. There are limited data on its indications, efficacy, and safety in Australia. We performed a multicenter retrospective cohort study of patients undergoing SIRT for HCC in all Sydney hospitals between 2005 and 2019. The primary outcome was overall survival. Secondary outcomes were progression-free survival and adverse events. During the study period, 156 patients underwent SIRT across 10 institutions (mean age 67 years, 81% male). SIRT use progressively increased from 2005 (n = 2), peaking in 2017 (n = 42) before declining (2019: n = 21). Barcelona Clinic Liver Cancer stages at treatment were A (13%), B (33%), C (52%), and D (2%). Forty-four (28%) patients had tumor thrombus. After a median follow-up of 13.9 months, there were 117 deaths. Median overall survival was 15 months (95% confidence interval 11-19). Independent predictors of mortality on multivariable analysis were extent of liver involvement, Barcelona Clinic Liver Cancer stage, baseline ascites, alpha fetoprotein, and model for end-stage liver disease score. Median progression-free survival was 6.0 months (95% confidence interval 5.1-6.9 months). Following SIRT, 11% of patients were downstaged to curative therapy. SIRT-related complications occurred in 17%: radioembolization-induced liver disease (11%), pneumonitis (3%), gastrointestinal ulceration, and cholecystitis (1% each). Baseline ascites predicted for radioembolization-induced liver disease. We present the largest Australian SIRT cohort for HCC. We have identified several factors associated with a poor outcome following SIRT. Patients with early-stage disease had the best survival with some being downstaged to curative therapy.

Sections du résumé

BACKGROUND AND AIM OBJECTIVE

METHODS METHODS

We performed a multicenter retrospective cohort study of patients undergoing SIRT for HCC in all Sydney hospitals between 2005 and 2019. The primary outcome was overall survival. Secondary outcomes were progression-free survival and adverse events.

RESULTS RESULTS

During the study period, 156 patients underwent SIRT across 10 institutions (mean age 67 years, 81% male). SIRT use progressively increased from 2005 (n = 2), peaking in 2017 (n = 42) before declining (2019: n = 21). Barcelona Clinic Liver Cancer stages at treatment were A (13%), B (33%), C (52%), and D (2%). Forty-four (28%) patients had tumor thrombus. After a median follow-up of 13.9 months, there were 117 deaths. Median overall survival was 15 months (95% confidence interval 11-19). Independent predictors of mortality on multivariable analysis were extent of liver involvement, Barcelona Clinic Liver Cancer stage, baseline ascites, alpha fetoprotein, and model for end-stage liver disease score. Median progression-free survival was 6.0 months (95% confidence interval 5.1-6.9 months). Following SIRT, 11% of patients were downstaged to curative therapy. SIRT-related complications occurred in 17%: radioembolization-induced liver disease (11%), pneumonitis (3%), gastrointestinal ulceration, and cholecystitis (1% each). Baseline ascites predicted for radioembolization-induced liver disease.

CONCLUSION CONCLUSIONS

We present the largest Australian SIRT cohort for HCC. We have identified several factors associated with a poor outcome following SIRT. Patients with early-stage disease had the best survival with some being downstaged to curative therapy.

Identifiants

DOI: 10.1111/jgh.15986 PMID: 36031345

pubmed: 36031345

doi: 10.1111/jgh.15986

doi:

Substances chimiques

Yttrium Radioisotopes 0

Sirtuins EC 3.5.1.-

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

2173-2181

Informations de copyright

Références

Villanueva A. Hepatocellular carcinoma. N. Engl. J. Med. 2019; 380: 1450-1462.

European Association For The Study Of The Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2018; 69: 182-236.

Yang JD, Hainaut P, Gores GJ et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019: 1-16.

Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther. Adv. Med. Oncol. 2020; 12: 1758835920970840.

Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J. Hepatol. 2012; 56: 464-473.

Kalogeridi M-A, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, Kouloulias V. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J. Hepatol. 2015; 7: 101-112.

Rostambeigi N, Dekarske AS, Austin EE, Golzarian J, Cressman EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2014; 25: 1075-1084.

Kulik LM, Carr BI, Mulcahy MF et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.

Iñarrairaegui M, Thurston KG, Bilbao JI et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J. Vasc. Interv. Radiol. 2010; 21: 1205-1212.

Lucà MG, Nani R, Schranz M et al. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncol. 2018; 14: 727-735.

Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18: 1624-1636.

Chow PK, Gandhi M, Tan SB et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J. Clin. Oncol. 2018; 36: 1913-1921.

Ricke J, Klümpen HJ, Amthauer H et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J. Hepatol. 2019; 71: 1164-1174.

Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750.

Gil-Alzugaray B, Chopitea A, Iñarrairaegui M et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57: 1078-1087.

Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.

Sangro B, Carpanese L, Cianni R et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878.

Hirsch RD, Mills C, Sawhney R et al. SIRT compared with DEB-TACE for hepatocellular carcinoma: a real-world study (the SITAR study). J. Gastrointest. Cancer 2021; 52: 907-914.

Mazzaferro V, Sposito C, Bhoori S et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57: 1826-1837.

Kokabi N, Camacho JC, Xing M, el-Rayes BF, Spivey JR, Knechtle SJ, Kim HS. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer 2015; 121: 2164-2174.

Abouchaleh N, Gabr A, Ali R et al. 90Y Radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J. Nucl. Med. 2018; 59: 1042-1048.

Ozkan ZG, Poyanli A, Ucar A et al. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biother. Radiopharm. 2015; 30: 132-138.

Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 2020; 382: 1894-1905.

Vogel A, Rimassa L, Sun H-C et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. Liver Cancer 2021; 10: 240-248.

Iñarrairaegui M, Sangro B. Selective internal radiation therapy approval for early HCC: what comes next? Hepatology 2021; 74: 2333-2335.

Salem R, Johnson GE, Kim E et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology 2021; 74: 2342-2352.

Reig M, Forner A, Rimola J et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 2021.

Bekki Y, Marti J, Toshima T et al. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery 2021; 169: 1044-1051.

Sangro B, D'Avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin. Pharmacother. 2011; 12: 1057-1073.

McAleese J, Mooney L, Walls G. Reducing the risk of death from Pneumocystis jirovecii pneumonia after radical radiation therapy to the lung. Clin. Oncol. 2021; 33: 780-787.